Disclosure of financial competing interests in randomised controlled trials: cross sectional review

doi:10.1136/bmj.326.7388.526

BMJ 2003;326:526-527 ( 8 March )

Papers

Disclosure of financial competing interests in randomised controlled trials: cross sectional review

Cary P Gross, assistant professor ^a, Anu R Gupta, clinical scholar ^b, Harlan M Krumholz, associate professor of medicine ^c.

^a Section of General Internal Medicine, Department of Medicine,Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA, ^b Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine, ^c Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine

Correspondence to: C P Gross cary.gross@yale.edu

The first 150 words of the full text of this article appear below.

Financial relationships among industry, investigators, and academic institutions are growing increasingly complex, raisingconcerns about sponsors' considerable and perhaps inappropriateinvolvement in the conduct and reporting of biomedical research. ¹ ² Medical journals use disclosure as a primary mechanism for managingthese conflicts, and many have adopted the 1997 uniform requirementsfor manuscripts submitted to biomedical journals to guide thisprocess.³

According to the 1997 uniform requirements, authors are asked to "acknowledge in the manuscript all financial support fortheir work."³ For industry support for specific projects, authorsare asked to describe the sponsor's role in the design, analysis,and reporting of the study data.³ If there has been no suchinvolvement, the manuscript is expected to explicitly state thisfact.³

Previous work has shown that many published papers do not contain statements of financial competing interests.⁴ However,little is known about journals' adherence to other parts of thedisclosure guidelines or about the . . . [Full text of this article]

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

Technorati What's this?

This article has been cited by other articles:

Riechelmann, R. P., Wang, L., O'Carroll, A., Krzyzanowska, M. K. (2007). Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology. JCO 25: 4642-4647 [Abstract] [Full text]
Hampson, L. A., Joffe, S., Fowler, R., Verter, J., Emanuel, E. J. (2007). Frequency, Type, and Monetary Value of Financial Conflicts of Interest in Cancer Clinical Research. JCO 25: 3609-3614 [Abstract] [Full text]
McCabe, C. (2007). Guidance on Good Practice in Cost-Effectiveness Modeling: Is More Needed?. Med Decis Making 27: 350-351
Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., Nierenberg, A. A. (2005). Industry Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry. Am. J. Psychiatry 162: 1957-1960 [Abstract] [Full text]
Lexchin, J. R (2005). Implications of Pharmaceutical Industry Funding on Clinical Research. The Annals of Pharmacotherapy 39: 194-197 [Abstract] [Full text]
Bottomley, A., Efficace, F., Thomas, R., Vanvoorden, V., Ahmedzai, S. H. (2003). Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials. JCO 21: 2982-2992 [Abstract] [Full text]